Myocardial cell-to-cell communication via microRNAs

Ottaviani, Lara; Sansonetti, M; Martins, Paula

doi:10.1016/j.ncrna.2018.05.004

Cited by 23 publications

(19 citation statements)

References 123 publications

(163 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These three groups of ncRNAs can be detected in blood and other body fluids, such as urine and breast milk, and can act as powerful tools for detection and therapy of cardiac diseases, including cardiac fibrosis [4,50,143]. The function of ncRNAs during cardiac remodeling, involves them being secreted from some cells, and then being actively taken up by other target cells, thus contributing to cell-cell communications and paracrine signaling pathways [144][145][146][147][148].…”

Section: Non-coding Rnasmentioning

confidence: 99%

TGF-β and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus

et al. 2020

View full text Add to dashboard Cite

Cardiac fibrosis describes the inappropriate proliferation of cardiac fibroblasts (CFs), leading to accumulation of extracellular matrix (ECM) proteins in the cardiac muscle, which is found in many pathophysiological heart conditions. A range of molecular components and cellular pathways, have been implicated in its pathogenesis. In this review, we focus on the TGF-β and WNT signaling pathways, and their mutual interaction, which have emerged as important factors involved in cardiac pathophysiology. The molecular and cellular processes involved in the initiation and progression of cardiac fibrosis are summarized. We focus on TGF-β and WNT signaling in cardiac fibrosis, ECM production, and myofibroblast transformation. Non-coding RNAs (ncRNAs) are one of the main players in the regulation of multiple pathways and cellular processes. MicroRNAs, long non-coding RNAs, and circular long non-coding RNAs can all interact with the TGF-β/WNT signaling axis to affect cardiac fibrosis. A better understanding of these processes may lead to new approaches for diagnosis and treatment of many cardiac conditions.

show abstract

Section: Non-coding Rnasmentioning

confidence: 99%

TGF-β and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus

et al. 2020

View full text Add to dashboard Cite

show abstract

“…12 Moreover, cardiac intracellular transfer of miRNA was also reported. 29 Whatever the mechanism for the local myocardial changes in miRNA expression, it may pose a key role in the pathophysiological process occurring in HF. 30 In our study, the expression levels of miR-125b-5p were almost twice as high in the CS than in the peripheral venous circulation.…”

Section: Discussionmentioning

confidence: 99%

Cardiac‐peripheral transvenous gradients of microRNA expression in systolic heart failure patients

et al. 2020

View full text Add to dashboard Cite

Aims The aims of the study are to assess the levels of coronary sinus (CS) miRNAs of systolic heart failure (HF) patients in samples obtained during cardiac resynchronization therapy (CRT) device implantation and compare them to the peripheral systemic venous miRNA expression. Methods and ResultsThe cardiac specific miRNA levels were assessed in 60 patients, 39 HF patients with reduced ejection fraction and 21 control patients. The levels of four cardiac specified miRNAs (miR-21-5p, miR-92b-3p, miR-125b-5p, and miR-133a-3p) were compared between the peripheral samples of HF and controls and between peripheral venous in CS in the HF groups. Compared with controls, HF patients had higher peripheral serum venous levels of miR-125b-5p and miR-133-3p. In the HF group, the levels of expression were higher for miR-125b-5p and lower for miR-92, and miR-21-5p in the CS, compared with the peripheral venous circulation. Conclusions The differences in miRNA expressions in CS compared with those in the periphery suggest that changes that may occur at the levels of the myocardial tissue in HF may be more relevant to our understanding of the biological linkage between miRNA expression and HF, than the traditional analysis of systemic serum miRNA expression. declare that they have no conflict of interest.Cardiac-peripheral transvenous gradients of microRNA expression in systolic heart failure patients 841 ESC Heart Failure 2020; 7: 835-843

show abstract

“…Intriguingly, although cardiac Troponin-I did not significantly correlate with cardiac miRNAs, it positively correlated with the plasma exosome level and exosomal cardiac miRNAs. To date, many other exo-miRNAs involved in HF initiation and progression have been identified [ 69 , 81 ]. Specifically, it has been shown that exo-miRNA-21-3p, exo-miRNA-132, exo-miRNA-200 participate in cardiac hypertrophy, whereas exo-miRNA-29 family members mediate fibrosis, and exo-miRNA-146a is causative of angiogenesis alterations [ 69 ].…”

Section: Exosomesmentioning

confidence: 99%

Traditional and Emerging Biomarkers in Asymptomatic Left Ventricular Dysfunction—Promising Non-Coding RNAs and Exosomes as Biomarkers in Early Phases of Cardiac Damage

Janjusevic

Fluca

Ferro

et al. 2021

IJMS

View full text Add to dashboard Cite

Heart failure (HF) is one of the major causes of morbidity and mortality worldwide and represents an escalating problem for healthcare systems. The identification of asymptomatic patients with underlying cardiac subclinical disease would create an opportunity for early intervention and prevention of symptomatic HF. Traditional biomarkers are very useful as diagnostic and prognostic tools in the cardiovascular field; however, their application is usually limited to overt cardiac disease. On the other hand, a growing number of studies is investigating the diagnostic and prognostic potential of new biomarkers, such as micro-RNAs (miRNA), long non-coding RNAs, and exosome cargo, because of their involvement in the early phases of cardiac dysfunction. Unfortunately, their use in asymptomatic phases remains a distant goal. The aim of this review is to gather the current knowledge of old and novel biomarkers in the early diagnosis of cardiac dysfunction in asymptomatic individuals.

show abstract

Myocardial cell-to-cell communication via microRNAs

Cited by 23 publications

References 123 publications

TGF-β and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus

TGF-β and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus

Cardiac‐peripheral transvenous gradients of microRNA expression in systolic heart failure patients

Traditional and Emerging Biomarkers in Asymptomatic Left Ventricular Dysfunction—Promising Non-Coding RNAs and Exosomes as Biomarkers in Early Phases of Cardiac Damage

Contact Info

Product

Resources

About